ARTICLE | Company News
Gilead, Theraclone deal
August 4, 2014 7:00 AM UTC
Theraclone granted Gilead exclusive rights to develop and commercialize products incorporating Theraclone’s preclinical broadly neutralizing HIV antibodies (bNAbs) for therapeutic applications. Therac...